( MENAFN - EIN Presswire) Hemophilia A Market Outlook Hemophilia A companies are BioMarin Pharmaceutical, Roche, ApcinteX, Novo Nordisk, Sanofi, Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer LAS VEGAS, NEVADA, UNITED STATES, May 27, 2024 /EINPresswire / -- DelveInsight's“Hemophilia A Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Hemophilia A market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hemophilia A Market Forecast Some of the key facts of the Hemophilia A Market Report: The Hemophilia A market size is anticipated to grow with a significant CAGR during the study period (2020-2034). The United States accounts for the largest market size (around 65%) of hematopoietic stem cell transplantation, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Myeloablative regimen, Nonmyeloablative/reduced-intensity regimen, filgrastim (G-CSF) + Mozobil, G-CSF + cyclophosphamide (CY) are some of the regimen and therapies currently being used in the market. Myeloablative regimen is expected to capture the largest market followed by potential upcoming drug Iomab-B. In September 2023, the US Food and Drug Administration (FDA) approved APHE.